Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
50 hedge funds and large institutions have $176M invested in Kezar Life Sciences in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 6 reducing their positions, and 5 closing their positions.
317% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 6
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
28% more funds holding
Funds holding: 39 → 50 (+11)
0.3% more ownership
Funds ownership: 4.89% → 5.19% (+0.3%)
20% less capital invested
Capital invested by funds: $220M → $176M (-$44.5M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$7.92M |
| 2 |
BlackRock
New York
|
+$7.68M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.64M |
| 4 |
SC
Slow Capital
Greenbrae,
California
|
+$3.87M |
| 5 |
FM
Frazier Management
Seattle,
Washington
|
+$2.37M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$15.9M |
| 2 |
CI
Cowen Inc
New York
|
-$6.72M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.01M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.42M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.83M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OFM
51
Omega Fund Management
Boston,
Massachusetts
| – | -$15.9M | -67,562 | Closed |
|
|
SFM
52
Sphera Funds Management
Tel Aviv,
Israel
| – | -$472K | -2,000 | Closed |
|
53
UBS Group
Zurich,
Switzerland
| – | -$45K | -190 | Closed |
|
|
CCA
54
Catalyst Capital Advisors
Huntington,
New York
| – | -$7K | -30 | Closed |
|
55
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$2K | -7 | Closed |
|
KZR Hedge Fund Activity: Q1 2019 in Review
50 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q1 2019, worth a combined $176M — down 20% from $220M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new KZR positions and 5 closed out — a net gain of 11 holders — while 25 added to existing stakes and 6 trimmed.
The largest buyer was BB Biotech, adding an estimated $7.92M. The largest seller was Omega Fund Management, exiting entirely with an estimated $15.9M sold.
- 50 institutional investors held Kezar Life Sciences (KZR) as of Q1 2019, up from 39 in Q4 2018.
- Funds reported $176M of Kezar Life Sciences stock for Q1 2019, down 20% quarter-over-quarter.
- 16 funds opened new Kezar Life Sciences positions in Q1 2019 and 5 closed out, a net change of +11 holders.
- The largest Kezar Life Sciences buyer in Q1 2019 was BB Biotech, an estimated $7.92M added.
- The largest Kezar Life Sciences seller in Q1 2019 was Omega Fund Management, an estimated $15.9M sold.
Based on aggregated 13F filings for Q1 2019.